Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen and Servier complete collaboration transaction

Amgen and Servier complete collaboration transaction

13th August 2013

Amgen has announced the completion of its product collaboration transaction with Servier, allowing the two companies to move ahead with their new alliance.

The firms have confirmed the early termination of the waiting period under the US Hart-Scott-Rodino Antitrust Improvements Act of 1976 pertaining to the cardiovascular product collaboration agreement, which was announced last month.

Under the terms of the arrangement, Amgen has obtained commercial rights in the US to Servier's oral heart failure and angina drug Procoralan, while also gaining an exclusive option to develop and commercialise the investigational molecule S38844 for cardiovascular diseases.

Meanwhile, Servier has received an exclusive European option to commercialise omecamtiv mecarbil – an activator of cardiac myosin that is being tested for potential applications in the treatment of heart failure in patients with systolic dysfunction.

The companies will be able to exercise their respective options for the investigational therapies up to completion of designated phase II studies.ADNFCR-8000103-ID-801624178-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.